Navigation Links
U.S. Pharmacopeia Aiding FDA in Improved Tests for Heparin Contamination
Date:4/14/2008

Suspected Contaminant Mimics Heparin

ROCKVILLE, Md., April 14 /PRNewswire/ -- The United States Pharmacopeial (USP) Convention announces that it is working with the Food and Drug Administration (FDA) to develop more sensitive methods for detecting contaminants recently found in the widely used blood-thinning drug heparin. This contamination is suspected of causing severe allergic reactions in some patients and has resulted in over 60 deaths. The suspected contaminant, over-sulfated chondroitin, is derived from the dietary supplement chondroitin. The chemically-induced over-sulfated form can mimic blood-thinning properties. Consequently, heparin adulterated in this manner may pass existing quality tests. It is likely (but still being determined) that any deliberate adulteration was done for economic reasons, because over-sulfated chondroitin is a much less expensive ingredient than genuine heparin.

USP publishes official quality standards for medicines in the United States Pharmacopeia-National Formulary (USP-NF) and has worked with FDA for over 100 years in a unique public-private partnership that helps assure the quality of medicines in the United States. Following a recall in January of suspect heparin products, FDA in March asked USP to assist in re-assessing current tests and possibly developing new methods for detecting over-sulfated chondroitin in the heparin drug substance before it is made into a final product. This work is ongoing and will result in updated heparin monographs. Heparin has been sold in the United States since the 1940s and has had a USP monograph since 1950, which has been updated several times.

According to Roger L. Williams, M.D., USP's chief executive officer, "It is difficult for analytical procedures to detect and identify all adulterants. USP monographs are designed to test for known impurities that result from manufacture or degradation, not for unknown contaminants that may be added either accidentally or deliberately. USP will continue to work closely with FDA and other partners to develop the most effective approaches to assure the safety of heparin."

The availability of a good public monograph in the USP with allied reference materials is one of a series of safety nets that work to assure that U.S. patients and practitioners have access to good quality medicines. Other safety nets include dedicated and trusted drug ingredient and product manufacturers who follow good manufacturing practices (GMPs) and sound sampling protocols in support of batch release testing. Oversight from FDA is also key in assuring product quality along complicated and at times lengthy supply and distribution pathways.

USP will provide further information as its work evolves. For updates on the availability of this information, please contact Laura Provan at lnp@usp.org or 301-816-8268.

USP -- Advancing Public Health Since 1820

The United States Pharmacopeia (USP) is a private, non-profit, standards-setting organization that advances public health by helping to ensure the quality and consistency of medicines, food ingredients, and dietary supplements, promoting the safe and proper use of medications, and verifying ingredients in drugs and dietary supplements. Its standards, which are recognized worldwide, are developed by a unique process of public involvement through the contributions of volunteers representing pharmacy, medicine, and other health care professions, as well as science, academia, government, the pharmaceutical and food industries, and consumer organizations. For more information about USP and its public health programs, visit http://www.usp.org/newscenter.


'/>"/>
SOURCE U.S. Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Pharmacopeia Releases New Edition of the Food Chemicals Codex
2. US Pharmacopeia releases new edition of the Food Chemicals Codex
3. Pharmacopeia to Present at The Roth 20th Annual OC Growth Stock Conference
4. USP publishes Spanish edition of United States Pharmacopeia and National Formulary
5. USP Publishes Spanish Edition of United States Pharmacopeia and National Formulary
6. U.S. Pharmacopeia 8th Annual MEDMARX(R) Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide
7. US Pharmacopeia partners with Quantros to enhance the MEDMARX patient safety reporting program
8. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
9. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
10. Pharmacopeia Announces Senior Additions to Management Team
11. Twin findings raise hopes of improved anemia treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... , ... June 25, 2017 , ... CareSet Labs released ... in New Orleans. This is a new, greatly improved version of the Doctor Referral ... (FOIA) requests by Fred Trotter and subsequently called the the “Doctor Referral Dataset” as ...
(Date:6/25/2017)... ... June 25, 2017 , ... June is Men’s Health Month and the ... common cancer among men in the U.S. and the third most common cause of cancer ... that one man in seven will be diagnosed with prostate cancer during his lifetime. ...
(Date:6/24/2017)... (PRWEB) , ... June 24, 2017 , ... ... in Erie, PA at the Sheraton Erie Bayfront and Erie Convention Center on ... based medicine experience, exhibits, a student quiz bowl, award and scholarship presentations, and ...
(Date:6/24/2017)... ... June 24, 2017 , ... The weather is heating up and ... and business owners should be aware that the summer months provide more than warmer ... locks and keys can be negatively affected from direct exposure to the sun. When ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality ... Management Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively ... Management Alerts and Dashboards provide near real-time data about patients admitted to and/or ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
(Date:5/30/2017)... Corp. (NASDAQ: DRIO), a leading global digital health company with mobile ... presenting at the 7th annual LD Micro Invitational on Tuesday, June ... of DarioHealth will be giving the presentation and meeting with investors. ... 7th, 2017 at the Luxe Sunset Bel Air Hotel and will ... About LD Micro LD Micro was founded ...
(Date:5/29/2017)... TEL AVIV, Israel, May 29, 2017  Cellect Biotechnology ... of innovative technology which enables the functional selection of ... financial results for the first quarter ended March 31 ... pleased with our accomplishments in the first quarter of ... the first quarter, we announced the treatment of the ...
Breaking Medicine Technology: